Early Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab

医学 乌斯特基努马 伊克泽珠单抗 银屑病 银屑病面积及严重程度指数 斑块性银屑病 析因分析 内科学 疾病严重程度 皮肤病科 胃肠病学 疾病 阿达木单抗 银屑病性关节炎 塞库金单抗
作者
M Augustin,Gaia Gallo,Kyoungah See,Missy McKean-Matthews,Russel Thomas Burge,Melinda Gooderham,Kristian Reich
出处
期刊:Journal of Drugs in Dermatology [SanovaWorks]
卷期号:21 (2): 122-126 被引量:11
标识
DOI:10.36849/jdd.6063
摘要

BACKGROUND: The identification of early treatment factors that predict the long-term success of maintenance therapy for psoriasis may help optimize individual therapy. OBJECTIVE: To determine early treatment response rates to ixekizumab and ustekinumab and assess whether early response was associated with stable long-term response to these treatments in patients with moderate-to-severe psoriasis. METHODS: This post hoc subgroup analysis of the IXORA-S study (NCT02561806) measured disease severity using the Psoriasis Area Severity Index (PASI) and determined the percentage of patients treated with ixekizumab or ustekinumab who showed PASI 50 at week 2 or 4 (early response) and assessed whether early response was associated with maintaining complete (PASI 100) or almost complete (PASI 90) skin clearance at 80% of monthly visits during weeks 16−52 of treatment (stable response). Nonresponder imputation was used for missing PASI response status. RESULTS: A numerically higher portion of patients treated with ixekizumab were early responders and were significantly more likely to achieve a stable PASI 90 response (P<.0001) or PASI 100 response (P<.0001) than patients treated with ustekinumab. Patients treated with ixekizumab or ustekinumab who were early responders were more likely to achieve a stable response of PASI 90 or 100 (odds ratio>1). CONCLUSION: In patients with moderate-to-severe psoriasis treated with ixekizumab or ustekinumab, early response was a significant factor in maintaining stable complete or almost complete skin clearance. Therefore, rapid response is a clinically relevant factor to consider when optimizing individual therapeutic strategies. J Drugs Dermatol. 2022;21(2):122-126. doi:10.36849/JDD.6063.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zjujirenjie发布了新的文献求助10
2秒前
2秒前
今者当歌完成签到,获得积分10
2秒前
薛亮完成签到,获得积分20
3秒前
3秒前
任性星星完成签到 ,获得积分10
3秒前
爆米花的应助被欣慰的千易采纳,获得10
3秒前
第一作者发布了新的文献求助10
3秒前
6秒前
6秒前
7秒前
8秒前
momo完成签到,获得积分10
8秒前
CXY关注了科研通微信公众号
9秒前
jeak完成签到,获得积分10
9秒前
桉_发布了新的文献求助10
10秒前
春夏爱科研完成签到,获得积分10
10秒前
JamesPei的应助被hualiyangmei采纳,获得10
10秒前
10秒前
秋风的应助被ally采纳,获得10
10秒前
JamesPei的应助被11采纳,获得10
10秒前
11秒前
英姑的应助被老实外绣采纳,获得10
11秒前
zyt完成签到,获得积分10
11秒前
英姑的应助被李易峰采纳,获得10
11秒前
12秒前
科研通AI6.4的应助被12345采纳,获得10
12秒前
蔚雨完成签到,获得积分10
13秒前
SciGPT的应助被尊敬鸿采纳,获得10
14秒前
Dylan发布了新的文献求助10
15秒前
饺子发布了新的文献求助10
15秒前
深情安青的应助被开心德地采纳,获得20
15秒前
清脆往事完成签到,获得积分10
15秒前
激动的夜梦完成签到,获得积分10
16秒前
努力科研完成签到,获得积分10
16秒前
大方的冥茗完成签到 ,获得积分10
17秒前
黄姗姗发布了新的文献求助10
17秒前
17秒前
17秒前
彭于晏的应助被向天一采纳,获得10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187707
求助须知:如何正确求助?哪些是违规求助? 9575782
关于积分的说明 21843037
捐赠科研通 7785576
什么是DOI,文献DOI怎么找? 3435097
关于科研通互助平台的介绍 2559495
邀请新用户注册赠送积分活动 2481986